Table 1 Baseline data of patients who were treated with PLH or PL regimen
Variable | PLH (n = 84) | PL (n = 86) | p-value |
|---|---|---|---|
Age, years | |||
 Median (range) | 52 (42–67) | 53 (43–69) | 0.124a |
Sex, n (%) | 0.575b | ||
 Male | 72 (85.7) | 4771 (82.6) |  |
 Female | 12 (14.3) | 15 (17.4) |  |
BMI, kg/m2 | |||
 Median (range) | 25.2 (16.7–42.1) | 25.3 (16.2–41.8) | 0.309a |
ECOG performance status, n (%) | 0.551b | ||
 0* | 38 (45.2) | 35 (40.7) |  |
 1** | 46 (54.8) | 51 (59.3) |  |
 Time since diagnosis, month(s) | 6 (1–12) | 6 (1–14) | 0.435a |
HCC aetiology, n (%) | 0.556b | ||
 Hepatitis B virus | 45 (53.6) | 48 (55.8) |  |
 Hepatitis C virus | 22 (26.2) | 26 (30.2) |  |
 Without viral hepatitis | 17 (20.2) | 12 (14.0) |  |
 AFP (ng/ml) | 3984.0 (82.0–49,534.0) | 4022.0 (79.0–51,462.0) | 0.101a |
Child-Pugh, n (%) | 0.616b | ||
 A | 71 (84.5) | 75 (87.2) |  |
 B | 13 (15.5) | 11 (12.8) |  |
BCLC | 0.791b | ||
 B | 22 (26.2) | 21 (24.4) |  |
 C | 62 (73.8) | 65 (75.6) |  |
ALBI grade, n (%) | 0.464b | ||
 1 | 20 (23.8) | 22 (25.6) |  |
 2 | 56 (66.7) | 60 (69.8) |  |
 3 | 8 (9.5) | 4 (4.6) |  |
Liver cirrhosis, n (%) | 0.954b | ||
 Absent | 27 (32.1) | 28 (32.6) |  |
 Present | 57 (67.9) | 58 (67.4) |  |
PD-L1 expression (CPS cut-off values)#, n (%) | 0.906b | ||
 1–20 | 42 (50.0) | 45 (52.3) |  |
 20–50 | 27 (32.1) | 24 (27.9) |  |
 50–100 | 15 (17.9) | 17 (19.8) |  |
Tumour thrombus, n (%) | 0.695b | ||
 Absent | 35 (41.7) | 31 (36.0) |  |
 Branch of portal vein | 36 (42.8) | 44 (51.2) |  |
 Main portal vein | 13 (15.5) | 11 (12.8) |  |
Extrahepatic metastasis, n (%) | 0.543b | ||
 Absent | 64 (76.2) | 62 (72.1) |  |
 Present | 20 (23.8) | 24 (27.9) |  |
 Duration of drugs (months) | 15 (1–33) | 12 (2–33) | 0.081a |
Number of metastatic sites, n (%) | 0.969b | ||
  < 3 | 7 (8.3) | 6 (7.0) |  |
  ≥ 3 | 64 (76.2) | 68 (79.1) |  |
 Unclear | 13 (15.5) | 12 (13.9) |  |